In the pharmaceutical development arena, experts like Jesper Kjerulff stand out. As Global project lead and Chief operations officer (COO) of PharmNovo, Jesper Kjerulff is instrumental in propelling the company's groundbreaking project, PN6047, and advancing the field of neuropathic pain management.
Read more →In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.
Read more →At the forefront of PharmNovo's journey towards pioneering solutions in pain relief stands Jarkko Kalliomäki, our esteemed Chief Medical Officer since September 2022. With his profound knowledge and unwavering commitment, Jarkko brings a unique perspective to our mission.
Read more →As PharmNovo advances into phase II clinical studies with drug candidate PN6047, Chief Scientific Officer David Kendall plays a crucial role in the company’s success. With three decades of expertise bridging academia and industry, his visionary leadership and groundbreaking ideas are instrumental.
Read more →PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.
Read more →We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.
Read more →